Novo Nordisk says oral version of Wegovy also works at reducing weight in a PhIII study
An oral version of Novo Nordisk’s obesity medication helped adults in a Phase III clinical trial lose up to 15% of their body weight, setting the stage for broader access to what may be one of the biggest drugs of the decade.
The late-stage trial of 667 adults, who had obesity or overweight with at least one comorbidity, showed taking 50 mg of the oral drug was better than placebo, Novo disclosed Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
